Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + bevacizumab + paclitaxel
- Development stage
- Phase 1
- Lead developer
- Bayer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
b-Safi Shahda-solid tumor refers to a combination therapy regimen consisting of the multikinase inhibitor sorafenib, the anti-VEGF monoclonal antibody bevacizumab, and the microtubule-stabilizing cytotoxic agent paclitaxel. This specific combination was evaluated in a Phase I dose-escalation and drug-interaction study (NCT00933803) led by investigator Safi Shahda at Indiana University for the treatment of advanced solid tumors. The regimen was designed to leverage the synergistic effects of inhibiting multiple signaling pathways involved in tumor cell proliferation and angiogenesis (via sorafenib and bevacizumab) while utilizing the antimitotic properties of paclitaxel. The study primarily focused on determining the safety, tolerability, and maximum tolerated dose (MTD) of this triplet combination in patients with refractory malignancies.
- Brand names
- Nexavar
- Other names
- Sorafenib, Bevacizumab, and Paclitaxel combinationNCT00933803 regimenNCT-00933803 regimenNCT 00933803 regimen
02
Targets
BRAF V600EFGFR1 (Fibroblast growth factor receptor 1)VEGFR-1 (Vascular endothelial growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on sorafenib + bevacizumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + bevacizumab + paclitaxel.